| Literature DB >> 33122172 |
Keivan Zandi1,2, Franck Amblard1,2, Katie Musall1,2, Jessica Downs-Bowen1,2, Ruby Kleinbard1,2, Adrian Oo1,2, Dongdong Cao3, Bo Liang3, Olivia O Russell1,2, Tamara McBrayer1,2, Leda Bassit1,2, Baek Kim1,2, Raymond F Schinazi4,2.
Abstract
Coronavirus disease 2019 (COVID-19) is a serious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2). Some reports claimed certain nucleoside analogs to be active against CoV-2 and thus needed confirmation. Here, we evaluated a panel of compounds and identified novel nucleoside analogs with antiviral activity against CoV-2 and HCoV-OC43 while ruling out others. Of significance, sofosbuvir demonstrated no antiviral effect against CoV-2, and its triphosphate did not inhibit CoV-2 RNA polymerase.Entities:
Keywords: COVID-19; Coronaviridaezzm321990; HCoV-OC43; SARS-CoV-2; antiviral agents; emtricitabine; lamivudine; nucleoside analogs; remdesivir; sofosbuvir
Year: 2020 PMID： 33122172 DOI： 10.1128/AAC.01652-20
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191